Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Sjogren's Syndrome”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Study completedNCT03865888
What this trial is testing

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

Who this might be right for
Dry EyeSjogren Syndrome
Pavly Moawd 60
Early research (Phase 1)Looking for participantsNCT03816345
What this trial is testing

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Who this might be right for
Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)WithdrawnNCT02027298
What this trial is testing

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

Who this might be right for
Primary Sjogren's SyndromeSecondary Sjogren's SyndromeInflammatory Arthritis+1 more
The Cleveland Clinic
Post-approval studies (Phase 4)Study completedNCT00438048
What this trial is testing

A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment

Who this might be right for
Primary SjogrenSecondary SjogrenXerostomia
Pontificia Universidad Catolica de Chile 76
Testing effectiveness (Phase 2)Looking for participantsNCT07264517
What this trial is testing

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Who this might be right for
Dry Eye Disease
Instituto Grifols, S.A. 100